Examining the Efficacy of Calcium Hydroxylapatite Filler With Integral Lidocaine in Correcting Volume Loss of the Jawline—A Pilot Study

BACKGROUND Patients seek 3-dimensional volume restoration of the jawline to obtain a "defined" line. Injection of filler into the jawline is not approved by the Food and Drug Administration; however, dermatologists have injected this area with positive results, minimal adverse events, and high patient satisfaction. OBJECTIVE This study explores the efficacy of premixed calcium hydroxylapatite filler with integral lidocaine [CaHA(+)] to correct volume defects of the jawline. It examines the longevity, safety, and patient satisfaction (up to 12 months) of CaHA(+) for jawline volume loss correction. MATERIALS AND METHODS This is a single-investigator, nonblinded study. Twenty subjects received CaHA(+) filler injection in the jawline, with follow-up evaluations conducted at 14 days, 6 weeks, and 3, 6, 9, and 12 months. RESULTS CaHA(+) injection in the jawline results in statistically significant restoration in volume and improvement in appearance lasting up to 12 months. Overall, subjects report "moderate" improvement on the Global Aesthetic Improvement Scale. CONCLUSION It is important for cosmetic surgeons and dermatologists to have access to data on the efficacy and safety of injectables. The data obtained in this study show that CaHA(+) is an effective and safe option to correct jawline volume loss and is associated with high patient satisfaction. Address correspondence and reprint requests to: Margit L.W. Juhász, MD, Dermatology Research Center, University of California—Irvine, 843 Health Sciences Road, Irvine, CA, 92697, or e-mail: margit.lw.juhasz@gmail.com Supported by a grant from Merz North America, Inc., including provision of study product. The authors have indicated no other significant interest with commercial supporters. © 2018 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2qLBSp2